Text Size

Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?

This study has been completed.
Sponsor:
Information provided by:
Sorlandet Hospital HF
ClinicalTrials.gov Identifier:
NCT00202709
First received: September 12, 2005
Last updated: July 27, 2011
Last verified: September 2005
History of Changes
  Purpose

The purpose of this study is to find out if Thought Field Therapy has effect on certain anxiety disorders; agoraphobia, social phobia, and post traumatic stress disorder (PTSD).


Condition Intervention
Agoraphobia
Social Phobia
PTSD
 Behavioral: Thought Field Therapy (TFT)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sorlandet Hospital HF:

Primary Outcome Measures:
  • Global symptom index (gsi) on the Symptom checklist 90 revised (SCL-90-R) [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Davidson Trauma Scale [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Liebowitz Social Anxiety Scale [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Fear Questionnaire (FQ) [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]
  • Sheehan Disability Scale [ Time Frame: Before treatment/wait list period, just after treatment, 3 months and 12 months after treatment. Group A also 6 months after treatment. ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: May 2002
Study Completion Date: August 2003
Primary Completion Date: August 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Thought Field Therapy (TFT)
Treatment with TFT, first one hour, then 1/2 hour.
 Behavioral: Thought Field Therapy (TFT)
Treatment with TFT twice in one week
Other Name: Wait list control
No Intervention: Wait list control

Detailed Description:

Thought Field Therapy is an alternative treatment method that has been shown, by casuistic reports, to give good results when applied for anxiety disorders. In this study 52 patients, with one or more of the diagnoses agoraphobia, social phobia and/or PTSD, where randomized to either treatment with TFT or a wait list. The treatment group all got treatment in one week. 2 1/2 months later both the treatment group and the control group were tested on the same items as before the treatment started. After this evaluation phase the control group got the same treatment as the treatment or study group. Both groups were evaluated 3 and 12 months after treatment, the study group also 6 months after treatment. 4 patients were omitted because they changed groups. The study were performed from May 2002 until June 2003.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • One or more of the study diagnoses agoraphobia, social phobia and/or PTSD

Exclusion Criteria:

  • Ongoing psychosis
  • Ongoing serious drug problems
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00202709

Locations
Norway
Sorlandet Hospital
Arendal, Norway, 4809
Sponsors and Collaborators
Sorlandet Hospital HF
Investigators
Principal Investigator: Audun C Irgens, MD Sorlandet Hospital HF
  More Information

No publications provided by Sorlandet Hospital HF

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Audun Irgens, MD, Sorlandet sykehus HF
ClinicalTrials.gov Identifier: NCT00202709     History of Changes
Other Study ID Numbers: SSHF-AUIR-1
Study First Received: September 12, 2005
Last Updated: July 27, 2011
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Keywords provided by Sorlandet Hospital HF:
Anxiety disorder
Thought Field Therapy
Psychotherapy
 Agoraphobia
Social Phobia
Post Traumatic Stress Disorder

Additional relevant MeSH terms:
Agoraphobia
Anxiety Disorders
Phobic Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 16, 2013